NCT06999174 Multiparametric MRI for Characterization of Hepatocellular Carcinoma
| NCT ID | NCT06999174 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Muenster |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 128 participants in total. It began in 2025-05-01 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC). The goal is to evaluate whether advanced MRI parameters can support noninvasive diagnostic assessments and personalized treatment plans for patients with HCC. The study is being conducted at a single university center in Germany and includes adult patients with confirmed or suspected HCC. Participants will undergo standardized multiparametric MRI examinations, and the imaging data will be correlated with clinical, pathological, and therapeutic outcomes. No study-specific interventions or medications will be administered.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Confirmed or suspected diagnosis of HCC * Scheduled to receive TACE or SIRT as part of standard clinical care * Eligibility for liver MRI * Willing and able to provide written informed consent Exclusion Criteria: * Contraindications to MRI (e.g., pacemakers, ferromagnetic implants, severe claustrophobia) * Known allergy or intolerance to gadolinium-based contrast agents * Renal insufficiency with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² * Pregnancy or breastfeeding * Inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06999174 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06999174 currently recruiting?
Yes, NCT06999174 is actively recruiting participants. Contact the research team at max.masthoff@ukmuenster.de for enrollment information.
Where is the NCT06999174 trial being conducted?
This trial is being conducted at Münster, Germany.
Who is sponsoring the NCT06999174 clinical trial?
NCT06999174 is sponsored by University Hospital Muenster. The trial plans to enroll 128 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.